Free Newsletter
Register for our Free Newsletters
Advanced Composites
Amorphous Metal Structures
Analysis and Simulation
Asbestos and Substitutes
Associations, Research Organisations and Universities
Automation Equipment
Building Materials
Bulk Handling and Storage
CFCs and Substitutes
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

BASF and Bend Research join forces to solve bioavailability challenges

BASF SE : 25 February, 2013  (Company News)
BASF SE and Bend Research have signed an agreement to jointly evaluate and develop novel excipients to enhance the solubility and bioavailability of poorly soluble drugs.

The companies plan to combine their world-leading expertise in the development of new excipients and drug formulations to provide customers from the pharmaceutical industry with early access to the latest polymer innovations. The aim of this collaboration is to meet increasing challenges of poorly soluble active pharmaceutical ingredients (BCS Class II and IV compounds); the initial focus will be on optimizing new vinylpyrrolidone based copolymers being developed for the solubilization of poorly soluble active pharmaceutical ingredients.

BASF has extensive ingredient formulation and material science expertise, as well as excipient products. Bend Research is the leading formulation development and technology firm in the field of spray drying and has recently expanded capabilities in hot-melt extrusion.

For more than 35 years, Bend Research has worked on advancing new medicines that improve human health and to solve their most difficult scientific and technical problems. This success is based on the company’s ability to develop, advance, and commercialize pharmaceutical technologies, which grow from a solid base of scientific and engineering fundamental understanding. Bend Research Inc. provides several capabilities, including formulation and dosage-form support, assists in process development and optimization, manufactures clinical trial quantities of drug candidates in its cGMP facilities, and advances promising drug candidates from conception through commercialization. The company is a leader in novel formulations, including spray-dried dispersions and hot-melt extrusion formulations, as well as controlled-release, inhalation, and biotherapeutics technologies.

"We are excited about the opportunities this collaboration brings to us and our customers," said Rod Ray, CEO of Bend Research. "It offers early access to a different set of chemistries and allows us to develop and test customer formulations based on new polymers. BASF has an impressive track record developing and launching novel excipients. This deal complements our recently announced collaboration on cellulosics, because it gives us access to completely different chemistries."

"We are glad to bring our in-depth knowledge of polymeric excipients into this collaboration - to jointly extend the current toolbox already comprising innovations like Soluplus,” said Ralf Fink, Vice President Global Marketing at BASF Pharma Ingredients & Services business unit. “Coupled with Bend Research’s outstanding strengths in formulation development, including spray-drying and hot-melt extrusion, we are in an unique position to address the urgent solubility challenges relating to the development of drugs with poor bioavailability."

Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo